CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: March-15-18
Credit Expiration Date: March-15-19


Val R. Adams, PharmD, BCOP
Associate Professor
University of Kentucky College of Pharmacy
Department of Pharmacy Practice and Science
Lexington, KY

Meghan Karuturi, MD
Assistant Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Chad Barnett, PharmD, BCOP
Clinical Pharmacy Specialist - Breast Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Credit Hours

1.0 contact hours (.10 CEU)


Online Presentation

Program Description

Cyclin-dependent kinase (CDK) 4/6 inhibition significantly prolongs progression-free survival (PFS) in patients with metastatic breast cancer (mBRCA) whose disease progresses on endocrine therapies. This activity will examine emerging evidence and best practices supporting the use of CDK4/6 inhibitors.

This activity was originally presented as a webcast series on the following 4 dates: February 5, 8, 13, and 22, 2018. If you earned CPE credit for any of those events, you are not eligible to receive credit through this enduring online release.

Click here to review a short summary of Clinical Updates and Insights since this activity was launched.

Program Developer/Facilitator


Target Audience


Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss the role of CDK4/6 inhibition in ER+ and/or HR+, HER2-negative mBRCA.
  2. Describe the efficacy data from clinical trials for the FDA-approved CDK4/6 inhibitors and those in late-stage development.
  3. Review guideline recommendations for the use of CDK4/6 inhibitors for the management of mBRCA.
  4. Inform other members of the health care team about recommendations for the use of CDK inhibitors, including dosing, dose adjustments, safety monitoring, and drug interactions.
  5. Educate patients about potential AEs related to the use of CKD4/6 inhibitors and the importance of adherence to these oral medications.


Val R. Adams, PharmD, BCOP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
Meghan Karuturi, MD, has no relevant or financial relationships with a commercial interest to disclose.
Chad Barnett, PharmD, BCOP, has no relevant affiliations or financial relationships with a commercial interest to disclose.

The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education (CE) activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

Credit Statements

Pharmacist Accreditation Statement - Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-18-006-H01-P, 1.0 contact hours (.10 CEU).

Commercial Support Statements

This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Certificate Fee



2018 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Purdue University College of Medicine, MCM Education, Lilly, or Novartis Pharmaceuticals Corporation. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu